Business Update

Hollis-Eden provides update on negotiations for BioShield procurement contract

Published in Healthcare Finance, Tax and Law Weekly, December 6th, 2006

Hollis-Eden Pharmaceuticals, Inc., (HEPH) provided an update on its progress in negotiations with the U.S. Department of Health & Human Services (HHS) on a potential BioShield procurement contract for Neumune, the company's lead drug candidate for Acute Radiation Syndrome (ARS).

As previously announced, Hollis-Eden was informed by HHS in late June the company "is within the competitive range for discussion and further evaluation" on a potential procurement contract for Neumune. Hollis-Eden has been engaged since then in ongoing productive negotiations with HHS and has recently been advised that the company is still in the competitive range for an ARS contract award....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2006-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry